Enavogliflozin vs janagliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Enavogliflozin · Envlo
Marketed by Daewoong Pharmaceutical and partners
NCT04634500 · Phase 3 · completed
This Phase 3 trial randomly assigned 200 people with type 2 diabetes to enavogliflozin or to dapagliflozin, with participants and investigators unaware of assignment. It was designed to show enavogliflozin was not worse than dapagliflozin at lowering HbA1c over 24 weeks, within a margin of 0.35 percentage points. It met that test: HbA1c fell by 0.80 percentage points on enavogliflozin against 0.75 on dapagliflozin, a difference of 0.04 points (95% CI -0.21 to 0.12).
Next expected readout: December 2026 · NCT06399835 (registry estimate)
Reported efficacy
Change from baseline in HbA1c (at 24 weeks): Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35% (met)
Result source: NCT04634500
janagliflozin · Huiyoujing
Marketed by Hangzhou Zhongmei Huadong Pharmaceutical and partners
NCT03811548 · Phase 3 · status unknown
This randomised, double-blind, placebo-controlled Phase 3 trial randomised 432 drug-naive Chinese patients with type 2 diabetes 1:1:1 to placebo or janagliflozin 25 mg or 50 mg. The primary endpoint, HbA1c change at week 24, was met for both doses (placebo-adjusted -0.80% and -0.88%, P<0.001).
432 patients were randomised (publication); the registry's 442 is an estimate on a record not updated since 2020.
Next expected readout: December 2027 · NCT07244003 (registry estimate)
Reported efficacy
Change in HbA1c From Baseline to Week 24 (Baseline and Week 24): Placebo-adjusted HbA1c change at week 24: janagliflozin 25 mg -0.80% (95% CI -0.98 to -0.62), 50 mg -0.88% (95% CI -1.06 to -0.70); P<0.001 for both (Ji et al., Diabetes Obes Metab 2023) (met)
Result source: NCT03811548
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Enavogliflozin | janagliflozin |
|---|---|---|
| HbA1c, change | -0.8% vs -0.8%avs dapagliflozinNCT04634500 | —Not reported |
| Body weight, change (kg) | —Not posted · NCT05376969 | —Not reported |
| HbA1c below 7% | —Not posted · NCT05376969 | —Not reported |
| Fasting plasma glucose, change | —Not posted · NCT05376969 | —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT05376969 | —Not reported |
HbA1c, change
- Enavogliflozin
- -0.8% vs -0.8%avs dapagliflozinNCT04634500
- janagliflozin
- —Not reported
Body weight, change (kg)
- Enavogliflozin
- —Not posted · NCT05376969
- janagliflozin
- —Not reported
HbA1c below 7%
- Enavogliflozin
- —Not posted · NCT05376969
- janagliflozin
- —Not reported
Fasting plasma glucose, change
- Enavogliflozin
- —Not posted · NCT05376969
- janagliflozin
- —Not reported
3-point MACE (% with event)
- Enavogliflozin
- —Not posted · NCT05376969
- janagliflozin
- —Not reported
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Enavogliflozin
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Enavogliflozin's landscape · janagliflozin's landscape